MY01 Inc. Receives FDA Clearance for the MY01 Continuous Compartment Pressure Monitor as an Aid in Diagnosis of Compartment Syndrome
- MY01
MONTREAL, May 6, 2021 /PRNewswire/ – MY01’s device helps diagnose acute compartment syndrome (ACS), a relatively common and potentially lethal muscle condition notably suffered by Tiger Woods in his car accident last February. Because current diagnostic tools rely on a patient’s inherently subjective pain description, ACS diagnosis is often misdiagnosed or missed entirely and is the main cause of lost lawsuits against orthopedic surgeons in the U.S. Read more…
Related Reading
News / Regulatory Affairs
i-GENTIC AI Expands GENIE to Enforce Full FDA Compliance Lifecycle for Life Sciences
May 4, 2026
PALO ALTO, CA, UNITED STATES, May 4, 2026 / EINPresswire.com / — Biopharma and medtech companies face a years-long process to get their products approved. Drug and device makers navigate a full spectrum of FDA and global regulatory frameworks to move innovation forward.
Blog / Coverage & Payment / Government & Legislative Affairs / Health Access / Regulatory Affairs
A Policy Win for Maternal Health Innovation Through FDA–CMS Collaboration
April 27, 2026
The United States faces a maternal health crisis demanding urgent action. The U.S. has the worst maternal outcomes among high income nations. Our maternal mortality rates far exceed peer countries’, despite the highest per capita health care spending. Protecting mothers and improving birth outcomes provides an important opportunity for bipartisan priority leadership.
Event / Regulatory Affairs
Compliance Considerations in an Active Deals Market for Medtech
June 17, 2026
12:00 PM – 1:00 PM
Join PwC to explore how compliance leaders can proactively support deal activity across the transaction lifecycle.
Event / Digital Health / Regulatory Affairs
AdvaMed® Cybersecurity Summit
November 10, 2026
Join cyber experts for the 2026 Cybersecurity Summit to address the latest industry issues and FDA requirements.
News / Regulatory Affairs / Small Business
Carbon Medical Technologies’ InjecSURE® Injection System Receives FDA 510(k) Clearance, Expanding CMT’s Portfolio of Urology Delivery Solutions
April 16, 2026
Saint Paul, MN – April 15, 2026. Carbon Medical Technologies, Inc. (CMT), a manufacturer of implantable medical devices and delivery systems utilizing proprietary technologies, is pleased to announce that its InjecSURE® Injection System has received clearance from the U.S. Food and Drug Administration (FDA) through the 510(k) pathway. This milestone marks the introduction of a new accessory system designed to support the delivery of syringe-based injectable materials into urethral tissues during cystoscopic procedures.
Blog / Business Development / Health Access / Small Business
Pro-Innovation Tax Policy Strengthens U.S. Medtech Leadership, Delivers for Patients
April 15, 2026
The tax incentives in the One Big Beautiful Bill Act passed by Congress and signed into law by President Trump last year are a prime example of the public policies reinforcing the U.S. position as the global leader in medtech innovation.
Resource / Regulatory Affairs
AdvaMed® Comment Letter to FDA: Exemptions from Premarket Notification Requirements for Class II Devices
April 15, 2026
AdvaMed’s® comments on FDA’s 510(k) exemption framework for Class II devices and its impact on innovation and patient access.
News / Business Development / Government & Legislative Affairs / Small Business
AdvaMed Thanks President Trump, Congress for Legislation Restoring Programs That Jumpstart Early-stage Medtech Innovation
April 14, 2026
WASHINGTON—AdvaMed, the Medtech Association, the largest trade association representing medtech innovators, thanked President Trump and Congress for enacting the Small Business Innovation and Economic Security Act (S. 3971). Signed into law, the legislation reauthorizes the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.